Joseph Michael Fitzgerald - 13 Feb 2026 Form 4 Insider Report for BOSTON SCIENTIFIC CORP (BSX)

Reporting relationship: EVP & Group Pres, Cardiology
Issuer ticker: BSX
Reported as of: 13 Feb 2026
Net transaction value: -$2,757,537
SEC form: 4
Accepted by SEC: 18 Feb 2026, 17:58:50 UTC
Prior SEC filing: 17 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Susan Thompson, Attorney-in-Fact

Key filing fact

Joseph Michael Fitzgerald filed Form 4 for BOSTON SCIENTIFIC CORP (BSX) on 18 Feb 2026.

Key facts

This page summarizes Joseph Michael Fitzgerald's Form 4 filing for BOSTON SCIENTIFIC CORP (BSX).
11 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 18 Feb 2026, 17:58.

Change

Previous filing in this sequence was filed on 17 Feb 2026.
Current net transaction value: -$2,757,537.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001484186 Primary reporting owner

Fitzgerald Joseph Michael

Relationship: EVP & Group Pres, Cardiology
Address: 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH
Signature: /s/ Susan Thompson, Attorney-in-Fact
Signature date: 18 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BSX transaction

Common Stock

Award

Transaction value: $0
Shares: +34,898
Change %: +21%
Price: $0.000000
Shares after: 204,790
Date: 13 Feb 2026
Ownership: Direct
Footnotes: F1

BSX transaction

Common Stock

Award

Transaction value: $0
Shares: +34,898
Change %: +17%
Price: $0.000000
Shares after: 239,688
Date: 13 Feb 2026
Ownership: Direct
Footnotes: F2

BSX transaction

Common Stock

Options Exercise

Transaction value: $0
Shares: +2,797
Change %: +1.2%
Price: $0.000000
Shares after: 242,485
Date: 13 Feb 2026
Ownership: Direct
Footnotes: F3

BSX transaction

Common Stock

Tax liability

Transaction value: $2,473,862
Shares: -33,104
Change %: -14%
Price: $74.73
Shares after: 209,381
Date: 13 Feb 2026
Ownership: Direct

BSX transaction

Common Stock

Options Exercise

Transaction value: $0
Shares: +4,362
Change %: +2.1%
Price: $0.000000
Shares after: 213,743
Date: 14 Feb 2026
Ownership: Direct
Footnotes: F3

BSX transaction

Common Stock

Tax liability

Transaction value: $148,713
Shares: -1,990
Change %: -0.93%
Price: $74.73
Shares after: 211,753
Date: 14 Feb 2026
Ownership: Direct

BSX transaction

Common Stock

Options Exercise

Transaction value: $0
Shares: +3,960
Change %: +1.9%
Price: $0.000000
Shares after: 215,713
Date: 16 Feb 2026
Ownership: Direct
Footnotes: F3

BSX transaction

Common Stock

Tax liability

Transaction value: $134,962
Shares: -1,806
Change %: -0.84%
Price: $74.73
Shares after: 213,907
Date: 16 Feb 2026
Ownership: Direct

BSX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 5,234
Date: 13 Feb 2026
Ownership: By Child
Footnotes: F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BSX transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -2,797
Change %: -25%
Price: $0.000000
Shares after: 8,391
Date: 13 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,797
Exercise price
Footnotes: F3, F5

BSX transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -4,362
Change %: -50%
Price: $0.000000
Shares after: 4,363
Date: 14 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 4,362
Exercise price
Footnotes: F3, F6

BSX transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -3,960
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 16 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,960
Exercise price
Footnotes: F3, F7

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 7 footnotes

Footnote F1

On February 14, 2023, the reporting person was awarded a target number of performance share units under the Company's 2023 Organic Net Sales Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's organic net sales performance measured against its financial plan over the three-year performance cycle comprising the three-year period ended December 31, 2025 and subject to the completion of the concurrent three-year individual service period. On February 13, 2026, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied.

Footnote F2

On February 14, 2023, the reporting person was awarded a target number of performance share units under the Company's 2023 Total Shareholder Return Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Health Care Index over the three-year performance cycle comprising the three-year period ended December 31, 2025 and subject to the completion of the concurrent three-year individual service period. On February 13, 2026, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied.

Footnote F3

Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

Footnote F4

The reporting person disclaims beneficial ownership of the shares held by his child, and this report should not be deemed an admission that the reporting person is the beneficial owner of his child's shares for purposes of Section 16 or for any other purpose.

Footnote F5

Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant.

Footnote F6

Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant.

Footnote F7

Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant.